DOCSLIB.ORG

Epidermal Growth Factor Receptor, P53 Mutation, and Pathological

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epidermal Growth Factor Receptor, P53 Mutation, and Pathological Vol. 9, 6461–6468, December 15, 2003 Clinical Cancer Research 6461 Epidermal Growth Factor Receptor, p53 Mutation, and Pathological Response Predict Survival in Patients with Locally Advanced Esophageal Cancer Treated with Preoperative Chemoradiotherapy log rank) correlated with 0.051 ؍ Michael K. Gibson,1 Susan C. Abraham,2 and p53 mutation (P Tsung-Teh Wu,3 Barbara Burtness,4 increased OS, whereas increased EGF-R expression pre- ؍ Richard F. Heitmiller,5 Elisabeth Heath,1 and dicted poor OS (P 0.009 log rank). EGF-R remained 1 significant when adjusted for clinical covariates. There was Arlene Forastiere a trend toward increased OS related to better tumor differ- 1Division of Medical Oncology, The Sidney Kimmel Comprehensive 2 entiation and decreased bcl-2. Cancer Center at Johns Hopkins, Baltimore, Maryland; Department Conclusions: These data suggest that EGF-R and p53 of Pathology, Mayo Clinic, Rochester, Minnesota; 3Department of Pathology, The University of Texas M. D. Anderson Cancer Center, mutation may be used as both outcome predictors and tar- Houston, Texas; 4Department of Internal Medicine, Yale University gets for molecular therapy for esophageal cancer. School of Medicine, New Haven, Connecticut; and 5Department of Surgery, Union Memorial Hospital, Baltimore, Maryland INTRODUCTION Esophageal cancer comprises a small percentage (1.5%) ABSTRACT and low incidence (12,300 cases/year) of total cancer cases in Purpose: Despite the availability of cellular markers the United States; however, the mortality rate remains high (1, associated with cell cycle, apoptosis, and DNA repair, pre- 2). In our experience and the experience of others, locally dictive factors for pathological complete response (CR) and advanced, nonmetastatic disease is curable in up to 40% of overall survival (OS) are few in patients with locally ad- patients (3–5). Overall survival with surgery alone ranges be- vanced esophageal cancer. This study evaluates the role of tween 15% and 25% (6). These rates likely reflect both late clinical and cellular markers in predicting CR and OS in stage of disease at diagnosis as well as inadequacy of therapy. patients with esophageal cancer. Although survival results in phase II trials using preoper- Experimental Design: Patients were treated with infu- ative chemoradiotherapy are promising, randomized trials dem- sional cisplatin and 5-fluorouracil combined with daily ra- onstrate mixed results (7–10). Therefore, the role of this treat- diotherapy followed by esophagectomy. Pretreatment tu- ment approach remains controversial. Overall, standard were analyzed for epidermal growth factor preoperative chemoradiotherapy using cisplatin/5-fluorouracil (54 ؍ mors (n receptor (EGF-R), bax, and bcl-2 expression by immunohis- (5-FU)-based regimens results in a pathological complete re- tochemistry and for p53 mutations by direct DNA sequenc- sponse (CR) rate of approximately 25%. There is often an ing of exons 5–8. Clinical covariates included patients’ age apparent improvement in survival and local control compared at enrollment; gender; Barrett’s metaplasia; and tumor lo- with results expected with historical controls of surgery alone. cation, histology, and differentiation. Logistic regression Over the past 10 years, we conducted two phase II trials at and survival analyses were used to evaluate the predictors. Johns Hopkins and Yale that provided intensive regimens of Results: Age ranged from 32 to 75 years; most patients cisplatin and 5-FU chemotherapy combined with radiotherapy were male (45 male; 9 female); and tumors were distal (47 before surgical resection (3–5, 11). The second trial also incor- distal; 7 mid), adenocarcinoma (41 adenocarcinomas; 13 porated postoperative chemotherapy with paclitaxel and cispla- squamous cell carcinomas), and moderately differentiated tin. Combined trial results demonstrated that 93% percent of 92 (33 moderate; 6 well; 15 poor). Female gender predicted CR patients underwent surgery and 87% were completely resected (odds ratio 7.5; 95% confidence interval, 1.4–41). The OS with negative margins. The pathological CR rate was 33%. At was 43% at 5 years. Presence of CR (P < 0.001 log rank) median follow-up of 63.5 months, median survival of all en- rolled patients was 35 months, and 5-year survival was 40%. Patients with a pathological CR did better (67% survival at 5 years, median not reached), whereas the remainder of the pa- tients had 5-year survival of 27% (median survival at 21 Received 3/17/03; revised 8/28/03; accepted 8/28/03. months; P Ͻ 0.001). Survival is promising, but toxicity during The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked therapy and limited tolerance of adjuvant chemotherapy suggest advertisement in accordance with 18 U.S.C. Section 1734 solely to that both novel therapies and better selection of patients for indicate this fact. aggressive treatment are warranted. Requests for reprints: Michael K. Gibson, The Sidney Kimmel Com- One strategy to improve the outcome of patients treated prehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Clinical Research Building, Room 186, 1650 Orleans Street, Baltimore, Mary- with chemoradiotherapy is to select treatment responders for land 21231-1000. Phone: (410)955-8838; Fax: (410)955-8587; E-mail: directed therapy. Current knowledge about the molecular mech- [email protected]. anisms of cancer-related pathways is facilitating numerous stud- Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2003 American Association for Cancer Research. 6462 Epidermal Growth Factor Receptor and Esophageal Cancer ies that attempt to identify molecular markers of both response Gy. Esophagogastrectomy was carried out approximately 4 to preoperative therapy and overall survival. Markers of interest weeks after completion of chemoradiotherapy in those patients include those associated with apoptosis (p53, bax, and bcl-2), without disease progression. Study J9528 differed from study cell cycle control (p16, p21, and cyclin D1), growth regulation J8908 in that patients were subsequently treated i.v. with adju- [epidermal growth factor receptor (EGF-R), transforming vant chemotherapy consisting of 135 mg/m2 paclitaxel for 24 h growth factor-␣, HER-2neu, Ki-67], and DNA repair (ERCC1), on day 1 and 75 mg/m2 cisplatin on day 2 repeated every 3 metastatic potential (tissue inhibitor of metalloproteinase, E- weeks for three cycles. cadherin), angiogenesis (vascular endothelial growth factor), The NIH CTC criteria were used to measure toxicity, and 6 and sensitivity to chemotherapy (P-glycoprotein, thymidylate appropriate dose adjustments and delays were made. All pa- synthase, glutathione S-transferase, and metallothionine; tients provided written informed consent, and the Institutional Ref. 12). Review Boards at Yale and Johns Hopkins approved both pro- Despite extensive study, there remain no clear candidate tocols. markers that predict pathological response, and there are only Follow-up after treatment involved medical oncology visits equivocal data for a limited number of markers that might at 4-month intervals for the first year and at 6-month intervals predict survival for patients treated with preoperative multimo- for the 2nd through 5th years. After 5 years, patients were dality therapy (13–17). Although the study by Harpole et al. evaluated annually. (14) contained mostly adenocarcinomas, many of the studies The primary outcome was pathological response in the involved only squamous cell histologies, despite the marked resected specimen. A CR was defined as the histological ab- increase in the incidence of adenocarcinoma (18, 19). The need sence of residual tumor in the resected esophageal specimen and for additional information about these mechanisms is becoming nodal tissue. A partial response was defined as residual malig- more pressing with the recent and ongoing development of nant cells in the resected specimen. Progressive disease was drugs that target these markers and pathways. defined as the presence of metastatic or unresectable disease Given the need for both better predictors of outcome and before surgery. The secondary outcome, survival, was defined identification of targets for directed therapy, we examined the as any patient remaining alive within 6 months of the time of role of clinical and cellular markers in predicting pathological final follow-up (October, 2002), regardless of the cause of response and overall survival in patients with locally advanced death. esophageal cancer who were treated with combined modality Tissue Samples and Immunohistochemistry (IHC). therapy at Johns Hopkins and Yale. Paraffin embedded, pretreatment tumor tissue was available for 54 of the 92 patients treated on protocols J8908 (n ϭ 34) and J9528 (n ϭ 20) at Johns Hopkins and Yale. All tissue was MATERIALS AND METHODS obtained by endoscopic biopsy of the primary esophageal tumor. Study Design. A total of 92 patients with histologically Unstained histopathological sections on ChemMate (Bio- confirmed invasive squamous cell carcinoma or adenocarci- Tek Solutions) slides were stained with an automated stainer in noma of the esophagus, gastroesophageal junction, or gastric the Johns Hopkins Immunopathology Laboratory per methods cardia were enrolled in two phase II clinical trials (3, 4). All used in studies of colorectal cancer described previously (20, patients were newly diagnosed and had received no prior treat- 21).
Load more

Recommended publications
  • Homeobox Gene Expression Profile in Human Hematopoietic Multipotent
    Leukemia (2003) 17, 1157–1163 & 2003 Nature Publishing Group All rights reserved 0887-6924/03 $25.00 www.nature.com/leu Homeobox gene expression profile in human hematopoietic multipotent stem cells and T-cell progenitors: implications for human T-cell development T Taghon1, K Thys1, M De Smedt1, F Weerkamp2, FJT Staal2, J Plum1 and G Leclercq1 1Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium; and 2Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands Class I homeobox (HOX) genes comprise a large family of implicated in this transformation proces.14 The HOX-C locus transcription factors that have been implicated in normal and has been primarily implicated in lymphomas.15 malignant hematopoiesis. However, data on their expression or function during T-cell development is limited. Using degener- Hematopoietic cells are derived from stem cells that reside in ated RT-PCR and Affymetrix microarray analysis, we analyzed fetal liver (FL) in the embryo and in the adult bone marrow the expression pattern of this gene family in human multipotent (ABM), which have the unique ability to self-renew and thereby stem cells from fetal liver (FL) and adult bone marrow (ABM), provide a life-long supply of blood cells. T lymphocytes are a and in T-cell progenitors from child thymus. We show that FL specific type of hematopoietic cells that play a major role in the and ABM stem cells are similar in terms of HOX gene immune system. They develop through a well-defined order of expression, but significant differences were observed between differentiation steps in the thymus.16 Several transcription these two cell types and child thymocytes.
    [Show full text]
  • Drosophila Pax6 Promotes Development of the Entire Eye-Antennal Disc, Thereby Ensuring Proper Adult Head Formation
    PAPER Drosophila Pax6 promotes development of the entire COLLOQUIUM eye-antennal disc, thereby ensuring proper adult head formation Jinjin Zhua, Sneha Palliyila, Chen Ranb, and Justin P. Kumara,1 aDepartment of Biology, Indiana University, Bloomington, IN 47405; and bDepartment of Biology, Stanford University, Stanford, CA 94305 Edited by Ellen V. Rothenberg, California Institute of Technology, Pasadena, CA, and accepted by Editorial Board Member Neil H. Shubin February 17, 2017 (received for review July 26, 2016) Paired box 6 (Pax6) is considered to be the master control gene for molecular battle among GRNs allows for the subdivision of the eye development in all seeing animals studied so far. In vertebrates, eye-antennal disc to be maintained within a single continuous it is required not only for lens/retina formation but also for the cellular field (13–16). Of the GRNs that are known to operate development of the CNS, olfactory system, and pancreas. Although within the eye-antennal disc, the retinal determination (RD) Pax6 plays important roles in cell differentiation, proliferation, and network, which controls eye development, is the best studied (17). patterning during the development of these systems, the underlying At the core of the RD network lie the Paired box 6 (Pax6) genes mechanism remains poorly understood. In the fruit fly, Drosophila eyeless (ey)andtwin of eyeless (toy), the SIX family member sine melanogaster, Pax6 also functions in a range of tissues, including oculis (so), the transcriptional coactivator eyes absent (eya), and the the eye and brain. In this report, we describe the function of Pax6 in Ski/Sno family member dachshund (dac)(17).
    [Show full text]
  • The Receptor Interacting Protein 1 Inhibits P53 Induction Through NF-KB Activation and Confers a Worse Prognosis in Glioblastoma
    Research Article The Receptor Interacting Protein 1 Inhibits p53 Induction through NF-KB Activation and Confers a Worse Prognosis in Glioblastoma Seongmi Park,1 Kimmo J. Hatanpaa,2,7 Yang Xie,3,8 Bruce E. Mickey,4,7 Christopher J. Madden,4,7 Jack M. Raisanen,2,7 Deepti B. Ramnarain,1 Guanghua Xiao,3 Debabrata Saha,5 David A. Boothman,8 Dawen Zhao,6 Robert M. Bachoo,1,7,8 Russell O. Pieper,9 and Amyn A. Habib1,7,8 Departments of 1Neurology, 2Pathology, 3Clinical Sciences, 4Neurosurgery, 5Radiation Oncology, and 6Radiology, 7Annette G. Strauss Center of Neurooncology, and 8Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas and 9Department of Neurological Surgery, University of California-San Francisco, San Francisco, California Abstract studies have linked components of the NF-nB signaling pathway to Nuclear factor-KB (NF-KB) activation may play an important cell cycle progression and tumorigenesis (11–16). role in the pathogenesis of cancer and also in resistance to An intriguing mechanism underlying the pathogenesis of treatment. Inactivation of the p53 tumor suppressor is a key inflammation-induced cancer is the negative regulation of tumor component of the multistep evolution of most cancers. Links suppressor pathways by inflammatory and stress-induced signals. between the NF-KB and p53 pathways are under intense p53 is a key tumor suppressor altered in a broad range of human investigation. In this study, we show that the receptor cancers, including glioma, and an important outcome of p53 interacting protein 1 (RIP1), a central component of the activation is cell cycle arrest or apoptosis after DNA damage K (17, 18).
    [Show full text]
  • Role of Estrogen Receptor in Breast Cancer Cell Gene Expression
    4046 MOLECULAR MEDICINE REPORTS 13: 4046-4050, 2016 Role of estrogen receptor in breast cancer cell gene expression YABING ZHENG1, XIYING SHAO1, YUAN HUANG1, LEI SHI1, BO CHEN2, XIAOJIA WANG1, HONGJIAN YANG3, ZHANHONG CHEN1 and XIPING ZHANG3 Departments of 1Medical Oncology (Breast), 2Pathology and 3Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China Received April 28, 2015; Accepted February 23, 2016 DOI: 10.3892/mmr.2016.5018 Abstract. The aim of the present study was to establish the Europe in 2012, and the number of breast cancer-associated underlying regulatory mechanism of estrogen receptor (ER) mortalities is 131,000 (6). Furthermore, breast cancer is in breast cancer cell gene expression. A gene expression the most common cause of cancer-associated mortality in profile accession( no. GSE11324) was downloaded from the females. Therefore, it is essential to understand its molecular Gene Expression Omnibus (GEO) database. Differentially mechanism and develop more effective therapeutic methods expressed genes (DEGs) from an estrogen treatment group and for breast cancer treatment. a control group were identified. Chromatin immunoprecipita- The estrogen receptor (ER) is critical in determining the tion with high-throughput sequencing data (series GSE25710) phenotype of human breast cancers and is one of the most was obtained from the GEO for the ER binding sites, and important therapeutic targets (7). Furthermore, certain studies binding and expression target analysis was performed. A total have suggested that activation of ER is responsible for various of 3,122 DEGs were obtained and ER was demonstrated to biological processes, including cell growth and differentia- exhibit inhibition and activation roles during the regulation tion, and programmed cell death (8,9).
    [Show full text]
  • Interaction of the Human Androgen Receptor Transactivation Function with the General Transcription Factor TFIIF
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 8485–8490, August 1997 Biochemistry Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF IAIN J. MCEWAN* AND JAN-ÅKE GUSTAFSSON Department of Biosciences, Novum, Karolinska Institute, S-141 57 Huddinge, Sweden Communicated by Elwood V. Jensen, University of Hamburg, Hamburg, Germany, May 27, 1997 (received for review January 28, 1997) ABSTRACT The human androgen receptor (AR) is a tion factors, and thus the polymerase, to the promoter (re- ligand-activated transcription factor that regulates genes im- viewed in refs. 17–19). This can be achieved by direct contact portant for male sexual differentiation and development. To between the activator and the general transcription factors better understand the role of the receptor as a transcription andyor interactions by means of coactivator proteins (refs. 17 factor we have studied the mechanism of action of the N- and 19–21 and references therein). terminal transactivation function. In a protein–protein inter- In recent years a number of interactions have been described action assay the AR N terminus (amino acids 142–485) between members of the steroid–thyroid hormone receptor selectively bound to the basal transcription factors TFIIF and superfamily and basal transcription factors and co–activator the TATA-box-binding protein (TBP). Reconstitution of the proteins (see ref. 22 and references therein). However, very transactivation activity in vitro revealed that AR142–485 fused to little is known concerning the identity of interacting proteins the LexA protein DNA-binding domain was competent to with the human AR. To better understand the mechanism of activate a reporter gene in the presence of a competing DNA gene regulation by the human AR we have screened a panel of template lacking LexA binding sites.
    [Show full text]
  • DLX Genes: Roles in Development and Cancer
    cancers Review DLX Genes: Roles in Development and Cancer Yinfei Tan 1,* and Joseph R. Testa 1,2,* 1 Genomics Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA 2 Cancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA * Correspondence: [email protected] (Y.T.); [email protected] (J.R.T.) Simple Summary: DLX homeobox family genes encode transcription factors that have indispensable roles in embryonic and postnatal development. These genes are critically linked to the morphogene- sis of craniofacial structures, branchial arches, forebrain, and sensory organs. DLX genes are also involved in postnatal homeostasis, particularly hematopoiesis and, when dysregulated, oncogen- esis. DLX1/2, DLX3/4, and DLX5/6 exist as bigenes on different chromosomes, sharing intergenic enhancers between gene pairs, which allows orchestrated spatiotemporal expression. Genomic alterations of human DLX gene enhancers or coding sequences result in congenital disorders such as split-hand/foot malformation. Aberrant postnatal expression of DLX genes is associated with hematological malignancies, including leukemias and lymphomas. In several mouse models of T-cell lymphoma, Dlx5 has been shown to act as an oncogene by cooperating with activated Akt, Notch1/3, and/or Wnt to drive tumor formation. In humans, DLX5 is aberrantly expressed in lung and ovarian carcinomas and holds promise as a therapeutic target. Abstract: Homeobox genes control body patterning and cell-fate decisions during development. The homeobox genes consist of many families, only some of which have been investigated regarding a possible role in tumorigenesis. Dysregulation of HOX family genes have been widely implicated in cancer etiology.
    [Show full text]
  • New Structural Perspectives in G Protein-Coupled Receptor-Mediated Src Family Kinase Activation
    International Journal of Molecular Sciences Review New Structural Perspectives in G Protein-Coupled Receptor-Mediated Src Family Kinase Activation Sandra Berndt * and Ines Liebscher Rudolf Schönheimer Institute of Biochemistry, Molecular Biochemistry, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-341-9722175 Abstract: Src family kinases (SFKs) are key regulators of cell proliferation, differentiation, and survival. The expression of these non-receptor tyrosine kinases is strongly correlated with cancer development and tumor progression. Thus, this family of proteins serves as an attractive drug target. The activation of SFKs can occur via multiple signaling pathways, yet many of them are poorly understood. Here, we summarize the current knowledge on G protein-coupled receptor (GPCR)- mediated regulation of SFKs, which is of considerable interest because GPCRs are among the most widely used pharmaceutical targets. This type of activation can occur through a direct interaction between the two proteins or be allosterically regulated by arrestins and G proteins. We postulate that a rearrangement of binding motifs within the active conformation of arrestin-3 mediates Src regulation by comparison of available crystal structures. Therefore, we hypothesize a potentially different activation mechanism compared to arrestin-2. Furthermore, we discuss the probable direct regulation of SFK by GPCRs and investigate the intracellular domains of exemplary GPCRs with conserved polyproline binding motifs that might serve as scaffolding domains to allow such a direct interaction. Large intracellular domains in GPCRs are often understudied and, in general, not much Citation: Berndt, S.; Liebscher, I. is known of their contribution to different signaling pathways.
    [Show full text]
  • Expression and Function of Dlx Genes in the Osteoblast Lineage Haitao Li University of Connecticut School of Medicine and Dentistry
    University of Connecticut OpenCommons@UConn UCHC Articles - Research University of Connecticut Health Center Research 4-2008 Expression and Function of Dlx Genes in the Osteoblast Lineage Haitao Li University of Connecticut School of Medicine and Dentistry Inga Marijanovic University of Connecticut School of Medicine and Dentistry Mark S. Kronenberg University of Connecticut School of Medicine and Dentistry Ivana Erceg University of Connecticut School of Medicine and Dentistry Mary Louise Stover University of Connecticut School of Medicine and Dentistry See next page for additional authors Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons Recommended Citation Li, Haitao; Marijanovic, Inga; Kronenberg, Mark S.; Erceg, Ivana; Stover, Mary Louise; Velonis, Dimitrios; Mina, Mina; Upholt, William B.; Kalajzic, Ivo; and Lichtler, Alexander C., "Expression and Function of Dlx Genes in the Osteoblast Lineage" (2008). UCHC Articles - Research. 49. https://opencommons.uconn.edu/uchcres_articles/49 Authors Haitao Li, Inga Marijanovic, Mark S. Kronenberg, Ivana Erceg, Mary Louise Stover, Dimitrios Velonis, Mina Mina, William B. Upholt, Ivo Kalajzic, and Alexander C. Lichtler This article is available at OpenCommons@UConn: https://opencommons.uconn.edu/uchcres_articles/49 NIH Public Access Author Manuscript Dev Biol. Author manuscript; available in PMC 2009 May 9. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Dev Biol. 2008 April 15; 316(2): 458±470. doi:10.1016/j.ydbio.2008.01.001. Expression and Function of Dlx Genes in the Osteoblast Lineage Haitao Li1, Inga Marijanovic1, Mark S.
    [Show full text]
  • Two Independent and Interactive DNA-Binding Subdomains of the Pax6 Paired Domain Are Regulated by Alternative Splicing
    Downloaded from genesdev.cshlp.org on October 8, 2021 - Published by Cold Spring Harbor Laboratory Press Two independent and interactive DNA-binding subdomains of the Pax6 paired domain are regulated by alternative splicing Jonathan A. Epstein, 1'2 Tom Glaser, 2 Jiexing Cai, 2 Lisa Jepeal, 2 David S. Walton, 3 and Richard L. Maas 2"4 Divisions of Cardiology~ and Genetics2, Department of Medicine and Howard Hughes Medical Institute, Brigham and Women's Hospital, and Massachusetts Eye and Ear Infirmary, a Harvard Medical School, Boston, Massachusetts 02115 USA Vertebrate Pax proteins share a conserved 128-amino-acid DNA-binding motif, the paired domain. The PAX6 gene, which is mutated in the routine Small eye and human aniridia developmental defects, also encodes a second protein with a 14-amino-acid insertion in the paired domain. This protein, which arises by alternative mRNA splicing, exhibits unique DNA-binding properties. Unlike other paired domains, which bind DNA predominantly by their amino termini, the extended Pax6 paired domain interacts with DNA exclusively through its carboxyl terminus. This property can be simulated by deletion of 30 amino-terminal residues from the Pax6 or Pax2 paired domains. Thus, the insertion acts as a molecular toggle to unmask the DNA-binding potential of the carboxyl terminus. The functional nonequivalence of the two Pax6 proteins is underscored by a T ~ C mutation at position -3 of the alternative splice acceptor site that changes the ratio of the two isoforms and causes a distinct human ocular syndrome. [Key Words: Pax genes; transcription factor; alternative mRNA splicing; DNA binding; ocular development; aniridia] Received May 17, 1994; revised version accepted July 18, 1994.
    [Show full text]
  • PAX Genes in Childhood Oncogenesis: Developmental Biology Gone Awry?
    Oncogene (2015) 34, 2681–2689 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc REVIEW PAX genes in childhood oncogenesis: developmental biology gone awry? P Mahajan1, PJ Leavey1 and RL Galindo1,2,3 Childhood solid tumors often arise from embryonal-like cells, which are distinct from the epithelial cancers observed in adults, and etiologically can be considered as ‘developmental patterning gone awry’. Paired-box (PAX) genes encode a family of evolutionarily conserved transcription factors that are important regulators of cell lineage specification, migration and tissue patterning. PAX loss-of-function mutations are well known to cause potent developmental phenotypes in animal models and underlie genetic disease in humans, whereas dysregulation and/or genetic modification of PAX genes have been shown to function as critical triggers for human tumorigenesis. Consequently, exploring PAX-related pathobiology generates insights into both normal developmental biology and key molecular mechanisms that underlie pediatric cancer, which are the topics of this review. Oncogene (2015) 34, 2681–2689; doi:10.1038/onc.2014.209; published online 21 July 2014 INTRODUCTION developmental mechanisms and PAX genes in medical (adult) The developmental mechanisms necessary to generate a fully oncology. patterned, complex organism from a nascent embryo are precise. Undifferentiated primordia undergo a vast array of cell lineage specification, migration and patterning, and differentiate into an STRUCTURAL MOTIFS DEFINE THE PAX FAMILY SUBGROUPS ensemble of interdependent connective, muscle, nervous and The mammalian PAX family of transcription factors is comprised of epithelial tissues. Dysregulation of these precise developmental nine members that function as ‘master regulators’ of organo- programs cause various diseases/disorders, including—and genesis4 (Figure 1).
    [Show full text]
  • Pax Genes and Their Roles in Cell Differentiation and Development Ahmed Mansouri*, Marc Hallonetl and Peter Gruss
    851 Pax genes and their roles in cell differentiation and development Ahmed Mansouri*, Marc Hallonetl and Peter Gruss Members of the Pax gene family are expressed in various and in human aniridia [13]; in all of these, eye defects tissues during ontogenesis. Evidence for their crucial role are displayed. Pax2 is expressed during eye and kidney in morphogenesis, organogenesis, cell differentiation and development [14] and is mutated in a human family with oncogenesis is provided by rodent mutants and human kidney and eye abnormalities [15]. Pax genes clearly play diseases. Additionally, recent experimental in vivo and in vitro important roles during the formation of many structures. approaches have led to the identification of molecules that Furthermore, deregulated expression of Pax genes may interact with Pax proteins. lead to oncogenesis [16-18]. In this review, we focus on recent data documenting the Addresses role of Pax genes, and the interaction of the Pax proteins Department of Molecular Cell Biology, Max-Planck Institute for Biophysical Chemistry, Am Fassberg 11, D-37077 G/Sttingen, with other transcription factors, in the development of the Germany nervous system, in organogenesis and in cell proliferation *e-mail: [email protected] and differentiation. re-mail: [email protected] Se-mail: [email protected] Pax genes in the central nervous system Current Opinion in Cell Biology 1996, 8:851-857 The roles of Pax genes are particularly documented at © Current Biology Lid ISSN 0955-0674 the level of the nervous system, which consequently may represent a model for the study of the function of the Pax Abbreviations BMP bone morphogenetic protein genes.
    [Show full text]
  • Delta;Fosb Induction in Prefrontal Cortex by Antipsychotic
    Neuropsychopharmacology (2014) 39, 538–544 & 2014 American College of Neuropsychopharmacology. All rights reserved 0893-133X/14 www.neuropsychopharmacology.org DFosB Induction in Prefrontal Cortex by Antipsychotic Drugs is Associated with Negative Behavioral Outcomes 1,2,5 1,5 1,5 3 2 1 David M Dietz , Pamela J Kennedy , HaoSheng Sun , Ian Maze , Amy M Gancarz , Vincent Vialou , Ja Wook Koo1, Ezekiell Mouzon1, Subroto Ghose4, Carol A Tamminga4 and Eric J Nestler*,1 1 Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2 3 Department of Pharmacology and Toxicology and Institute on Addictions, University at Buffalo, Buffalo, NY, USA; Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, NY, USA; 4Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA DFosB, a FosB gene product, is induced in the prefrontal cortex (PFC) by repeated exposure to several stimuli including antipsychotic drugs such as haloperidol. However, the functional consequences of increased DFosB expression following antipsychotic treatment have not been explored. Here, we assessed whether DFosB induction by haloperidol mediates the positive or negative consequences or clinical-related actions of antipsychotic treatment. We show that individuals with schizophrenia who were medicated with antipsychotic drugs at their time of death display increased DFosB levels in the PFC, an effect that is replicated in rats treated chronically with haloperidol. In contrast, individuals with schizophrenia who were medication-free did not exhibit this effect. Viral-mediated overexpression of DFosB in the PFC of rodents induced cognitive deficits as measured by inhibitory avoidance, increased startle responses in prepulse inhibition tasks, and increased MK-801-induced anxiety-like behaviors.
    [Show full text]